An observational study in Castleman Disease, Castleman's Disease and Giant Lymph Node Hyperplasia, sponsored by University of Pennsylvania. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by University of Pennsylvania · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Castleman Disease with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Castleman Disease · United States.
Among the 14 studies in Castleman Disease with a site in United States, this one is one of 3 that started in 2016, is one of 5 observational ones, and was the 7th registered.
22 studies on the registry are indexed under Castleman Disease; 9 are open to participants now.
Browse Castleman Disease studies →4 of the 14 studies in Castleman Disease with a site in United States are open now. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 18–80
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Castleman Disease studies recruiting now, 7 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 14 across the 9 interventional studies, 280 across the 5 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 10 most frequent:
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.
Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.
University of Pennsylvania has 4 studies filed under Castleman Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Castleman Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02817997University of PennsylvaniaInternational Registry for Patients With Castleman Disease | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Castleman Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of the disease. Funding source - FDA OOPD.
This project is supported by the Castleman Disease Collaborative Network.
Visit the CDCN website at http://www.cdcn.org/accelerate to sign up for the ACCELERATE registry!
The ACCELERATE patient registry will give patients and families the opportunity to contribute their medical data to improve understanding of Castleman Disease. The patient registry will obtain real-world demographic, clinical, laboratory, and patient reported outcomes, and treatment data from 1000 patients worldwide with Castleman Disease.
This registry will help to provide important data for future Castleman Disease research studies. The patient registry helps centralize information on this rare disease, and provides researchers a way to obtain data on Castleman Disease patients. The major objectives for the registry include:
Individuals affected by Castleman Disease and families of deceased patients are invited to join the registry.
Patients located anywhere in the United States of America (USA), Canada, or rest of world will be able to enroll themselves directly into the registry. Participants will enroll online and be asked to provide their electronic medical records to University of Pennsylvania researchers for data extraction. All patients will also be asked to complete questionnaires every three months about their symptoms, treatments, and experiences with Castleman Disease. Complete participant information will be stored in a secure database.
Researchers who are interested in studying Castleman Disease can also request access to registry datasets.
Castleman Disease patients worldwide
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Common Symptoms
There is no intervention tested in this registry. We want determine what are common symptoms are associated with Castleman Disease. We will be examining the number of instances various symptoms such as fatigue, malaise, fever are recorded in the medical records.
Time frame: 5 years
Common Laboratory Abnormalities
There is no intervention tested in this registry. We want determine what are common laboratory abnormalities associated with Castleman Disease. We will be examining the values of specific laboratory values associated with Castleman's Disease such as C-Reactive Protein (CRP), ferritin, and hemoglobin recorded in the medical records.
Time frame: 5 years
Treatment
There is no intervention tested in this registry. We want determine what are common treatments used for patients with Castleman Disease. We will be examining the number of instances specific treatments such as steroids and chemotherapy are recorded in the medical records.
Time frame: 5 years
Survival
There is no intervention tested in this registry. Distribution of time-to-event variables will be estimated using standard survival analysis methods, including Kaplan-Meier product-limit survival curves. The median time to event with 2-sided 95% confidence intervals will be estimated.
Time frame: 5 years
Identify patient subtypes
We will use data collected through this study to identify patient subgroups, particularly those that are not responsive to current treatments
Time frame: 4 years
Identify clinical outcome measures
We will use data collected through this study to determine the optimal parameters for overarching clinical outcome measures for use in future trials
Time frame: 4 years
Identify clinical biomarkers
We will use data collected through this study to identify biomarkers of treatment response
Time frame: 4 years
Plan to share: Yes — Qualified Researchers, who apply for access to the database and are subsequently approved, will be given access to a limited dataset with direct identifiers removed in an Excel compatible file format or single SAS data files. The Certification \& Access Subcommittee will review applications from qualified researchers on an ongoing basis.
The record gives a start of Oct 2016, a primary completion of Sep 2027 and a completion of Sep 2027. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.